blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1256348

EP1256348 - REMEDIES FOR HEPATITIS C [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.03.2013
Database last updated on 24.08.2024
Most recent event   Tooltip03.07.2015Lapse of the patent in a contracting state
New state(s): TR		published on 05.08.2015  [2015/32]
Applicant(s)For all designated states
Mitsubishi Tanabe Pharma Corporation
2-10, Dosho-machi 3-chome Chuo-ku Osaka-shi
Osaka 541-8505 / JP
For all designated states
Japan as represented by Director General of Agency of National Institute of Infectious Deseases
23-1, Toyama 1-chome
Shijuku-ku
Tokyo 162-8640 / JP
[2012/18]
Former [2011/48]For all designated states
Mitsubishi Tanabe Pharma Corporation
2-10, Dosho-machi 3-chome Chuo-ku Osaka-shi
Osaka 541-8505 / JP
For all designated states
Japan as represented by Director General of Agency of National Institute of Infectious Deseases
23-1, Toyama 1-chome
Shijuku-ku
Tokyo 162-8640 / JP
Former [2008/22]For all designated states
Mitsubishi Tanabe Pharma Corporation
2-10, Dosho-machi 3-chome Chuo-ku Osaka-shi
Osaka 541-8505 / JP
For all designated states
JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
1-23-1, Toyama, Shinjuku-ku
Tokyo 162-8640 / JP
Former [2002/46]For all designated states
Mitsubishi Pharma Corporation
6-9, Hiranomachi 2-chome, Chuo-ku
Osaka-shi, Osaka 541-0046 / JP
For all designated states
JAPAN as represented by DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
1-23-1, Toyama, Shinjuku-ku
Tokyo 162-8640 / JP
Inventor(s)01 / ITAMI, Seima c/o Mitsubishi Pharma Corporation
Tokyo Head Office, 2-6 Nihonbashi-honcho 2-chome
Chuo-ku, Tokyo 103-8405 / JP
02 / SHIBUI, Tatsurou c/o Mitsubishi Pharma Corporation
Tokyo Head Office, 2-6 Nihonbashi-honcho 2-chome
Chuo-ku, Tokyo 103-8405 / JP
03 / SEKI, Makoto c/o Mitsubishi Pharma Corporation
Tokyo Head Office, 2-6 Nihonbashi-honcho 2-chome
Chuo-ku, Tokyo 103-8405 / JP
04 / YOTSUMOTO, Yoshihisa c/o Mitsubishi Pharma Corp.
Tokyo Head Office, 2-6 Nihonbashi-honcho 2-chome
Chuo-ku, Tokyo 103-8405 / JP
05 / MATSUURA, Yoshiharu
1-1314, 4-35, Yamadahigashi
Suita-shi, Osaka 565-0821 / JP
06 / MIYAMURA, Tatsuo
4-21-22-113, Hamadayama
Suginami-ku, Tokyo 168-0065 / JP
 [2012/18]
Former [2002/46]01 / ITAMI, Seima c/o Mitsubishi Pharma Corporation
Tokyo Head Office, 2-6 Nihonbashi-honcho 2-chome
Chuo-ku, Tokyo 103-8405 / JP
02 / SHIBUI, Tatsurou c/o Mitsubishi Pharma Corporation
Tokyo Head Office, 2-6 Nihonbashi-honcho 2-chome
Chuo-ku, Tokyo 103-8405 / JP
03 / SEKI, Makoto c/o Mitsubishi Pharma Corporation
Tokyo Head Office, 2-6 Nihonbashi-honcho 2-chome
Chuo-ku, Tokyo 103-8405 / JP
04 / YOTSUMOTO, Yoshihisa c/o Mitsubishi Pharma Corp.
Tokyo Head Office, 2-6 Nihonbashi-honcho 2-chome
Chuo-ku, Tokyo 103-8405 / JP
05 / MATSUURA, Yoshiharu
1-1314, 4-35, Yamadahigashi
Suita-shi, Osaka 565-0821 / JP
06 / MIYAMURA, Tatsuo
4-21-22-113, Hamadayama
Suginami-ku, Tokyo 168-0065 / JP
Representative(s)polypatent
An den Gärten 7
51491 Overath / DE
[N/P]
Former [2012/02]Polypatent
An den Gärten 7
51491 Overath / DE
Former [2010/01]Polypatent
Postfach 40 02 43
51410 Bergisch Gladbach / DE
Former [2002/46]Sternagel, Fleischer, Godemeyer & Partner Patentanwälte
An den Gärten 7
51491 Overath / DE
Application number, filing date01904385.013.02.2001
[2002/46]
WO2001JP00967
Priority number, dateJP2000003490614.02.2000         Original published format: JP 2000034906
[2002/46]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO0158459
Date:16.08.2001
Language:EN
[2001/33]
Type: A1 Application with search report 
No.:EP1256348
Date:13.11.2002
Language:EN
The application published by WIPO in one of the EPO official languages on 16.08.2001 takes the place of the publication of the European patent application.
[2002/46]
Type: B1 Patent specification 
No.:EP1256348
Date:02.05.2012
Language:EN
[2012/18]
Search report(s)International search report - published on:JP16.08.2001
(Supplementary) European search report - dispatched on:EP09.06.2005
ClassificationIPC:A61K31/737, A61K38/17, A61K39/395, A61K45/00, A61P31/20, C07K16/10, C12N15/09, G01N33/50, G01N33/53, G01N33/576
[2002/46]
CPC:
A61K31/737 (EP,US); A61K39/395 (KR); A61P31/20 (EP);
C07K16/109 (EP,US); A61K2039/505 (EP,US); C07K2317/21 (EP,US);
C07K2317/622 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2002/46]
TitleGerman:HEILMITTEL GEGEN HEPATITIS[2002/46]
English:REMEDIES FOR HEPATITIS C[2002/46]
French:REMEDES CONTRE L'HEPATITE C[2002/46]
Entry into regional phase20.08.2002Translation filed 
20.08.2002National basic fee paid 
20.08.2002Search fee paid 
20.08.2002Designation fee(s) paid 
20.08.2002Examination fee paid 
Examination procedure13.02.2001Request for preliminary examination filed
International Preliminary Examining Authority: JP
20.08.2002Examination requested  [2002/46]
10.09.2002Amendment by applicant (claims and/or description)
26.06.2008Despatch of a communication from the examining division (Time limit: M06)
30.12.2008Reply to a communication from the examining division
25.11.2010Despatch of a communication from the examining division (Time limit: M04)
01.04.2011Reply to a communication from the examining division
14.11.2011Communication of intention to grant the patent
20.03.2012Fee for grant paid
20.03.2012Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.06.2008
Opposition(s)05.02.2013No opposition filed within time limit [2013/15]
Fees paidRenewal fee
12.02.2003Renewal fee patent year 03
12.02.2004Renewal fee patent year 04
14.02.2005Renewal fee patent year 05
14.02.2006Renewal fee patent year 06
14.02.2007Renewal fee patent year 07
13.02.2008Renewal fee patent year 08
13.02.2009Renewal fee patent year 09
16.02.2010Renewal fee patent year 10
15.02.2011Renewal fee patent year 11
15.02.2012Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
FI02.05.2012
IT02.05.2012
NL02.05.2012
SE02.05.2012
TR02.05.2012
GR03.08.2012
ES13.08.2012
PT03.09.2012
[2015/32]
Former [2013/22]AT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
FI02.05.2012
IT02.05.2012
NL02.05.2012
SE02.05.2012
GR03.08.2012
ES13.08.2012
PT03.09.2012
Former [2013/11]AT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
FI02.05.2012
IT02.05.2012
NL02.05.2012
SE02.05.2012
GR03.08.2012
PT03.09.2012
Former [2013/08]AT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
FI02.05.2012
NL02.05.2012
SE02.05.2012
GR03.08.2012
PT03.09.2012
Former [2013/07]AT02.05.2012
BE02.05.2012
CY02.05.2012
FI02.05.2012
SE02.05.2012
GR03.08.2012
PT03.09.2012
Former [2013/04]BE02.05.2012
CY02.05.2012
FI02.05.2012
SE02.05.2012
GR03.08.2012
PT03.09.2012
Former [2013/01]CY02.05.2012
FI02.05.2012
SE02.05.2012
GR03.08.2012
PT03.09.2012
Former [2012/50]CY02.05.2012
FI02.05.2012
SE02.05.2012
GR03.08.2012
Former [2012/49]CY02.05.2012
FI02.05.2012
SE02.05.2012
Former [2012/48]FI02.05.2012
SE02.05.2012
Documents cited:Search[A]WO0005266  (CONNEX GES ZUR OPTIMIERUNG VON [DE], et al) [A] 1-74 * the whole document *;
 [PX]WO0026418  (UNIV LELAND STANFORD JUNIOR [US]) [PX] 1-74* the whole document *;
 [A]  - KOBAYASHI MASAKAZU ET AL, "Antibody response to E2/NS1 hepatitis C virus protein in patients with acute hepatitis C", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, (1997), vol. 12, no. 1, ISSN 0815-9319, pages 73 - 76, XP008047679 [A] 1-74 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1440-1746.1997.tb00350.x
International search[Y]WO9918198  (CHIRON SPA [IT], et al);
 [X]  - PILERI,P. ET AL., "Binding of hepatitis C virus to CD81", SCIENCE, (1998), vol. 282, pages 938 - 941, XP002939742

DOI:   http://dx.doi.org/10.1126/science.282.5390.938
 [Y]  - HIDE KIKUCHI, "Ketsueki baikai kansensho HCV", RINSHOU TO KENKYU, (1999), vol. 76, no. 7, pages 1260 - 1266, XP002945847
 [XP]  - TOBIAS ALLANDER ET AL., "Recombinant human monoclobal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81", JOURNAL OF GENERAL VIROLOGY, (200010), vol. 81, no. 10, pages 2451 - 2459, XP002939743
 [A]  - MIKE FLINT ET AL., "Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein", JOURNAL OF VIROLOGY, (1999), vol. 73, no. 8, pages 6782 - 6790, XP002939744
 [A]  - MIKE FLINT ET AL., "Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein", JOURNAL OF VIROLOGY, (200001), vol. 74, no. 2, pages 702 - 709, XP002939745

DOI:   http://dx.doi.org/10.1128/JVI.74.2.702-709.2000
Examination   - ISHII K. ET AL, "High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C.", HEPATOLOGY (BALTIMORE, MD.) OCT 1998 LNKD- PUBMED:9755251, (199810), vol. 28, no. 4, ISSN 0270-9139, pages 1117 - 1120
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.